Ramtin Agah bought $16k of RNXT
Chief Medical Officer at RenovoRx, Inc.. 20,000 shares at an average of $0.80, traded Apr 11, 2025, filed Apr 14, 2025.
Score components
- +15RoleOfficer
- 0Trade size$16k at market
- 0Relative to holdingsHoldings up 1.9%
- +18Price context0% above the 52-week low; 50% below the 52-week high
- +15Cluster4 insiders buying within 14 days
- +5Repeat buying3 buys in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +24.3%, 3m +65.7%, 6m +27.8%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001641172-25-003951, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Apr 11, 2025 | POpen-market purchase Common Stock | +20,000 | $0.80 | $16k | 1,098,460 | Apr 14, 2025 |
Related signals
Other insiders at RenovoRx, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 46Moderate | RNXTbuy RenovoRx, Inc. | Mark Voll Chief Financial Officer | $20k 25,000 shares | +21% | |
| 28Weak | RNXTbuy RenovoRx, Inc. | Ramtin Agah Chief Medical Officer | $9,975 10,000 shares | +1% | |
| 36Weak | RenovoRx, Inc. | Ramtin Agah Chief Medical Officer | $8,424 9,795 shares | +1% | |
| 31Weak | RenovoRx, Inc. | Ramtin Agah Chief Medical Officer | $169 205 shares | +0% | |
| 46Moderate | RenovoRx, Inc. | Shaun Bagai Chief Executive Officer | $4,507 5,000 shares | +1% | |
| 41Moderate | RenovoRx, Inc. | Shaun Bagai Chief Executive Officer | $4,262 5,000 shares | +2% | |
| 36Weak | RenovoRx, Inc. | Ramtin Agah Chief Medical Officer | $10k 12,000 shares | +2% | |
| 36Weak | RenovoRx, Inc. | Ramtin Agah Chief Medical Officer | $9,600 10,000 shares | +1% | |
| 33Weak | RNXTbuy RenovoRx, Inc. | Ramtin Agah Chief Medical Officer | $18k 22,000 shares | +3% | |
| 33Weak | RNXTbuy RenovoRx, Inc. | Shaun Bagai Chief Executive Officer | $9,297 10,000 shares | +3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.